BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 16220002)

  • 1. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between OX40/4-1 BB (CD134/CD137) costimulatory molecules expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):133-40. PubMed ID: 16232366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of costimulatory molecules OX40/4-1BB (CD134/CD137) detection on chosen mononuclear cells in children and adolescents with Graves' disease during methimazole therapy.
    Bossowski A; Stasiak-Barmuta A; Urban M; Bossowska A
    J Pediatr Endocrinol Metab; 2005 Dec; 18(12):1365-72. PubMed ID: 16459462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease.
    Bossowski A; Urban M; Stasiak-Barmuta A
    Pediatr Res; 2003 Sep; 54(3):425-9. PubMed ID: 12761360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of very late antigen-4 and lymphocyte function-associated antigen-1 on peripheral blood lymphocytes from patients with graves disease.
    Bossowski A; Urban M; Stasiak-Barmuta A; Turowski D
    Pediatr Res; 2002 Oct; 52(4):533-7. PubMed ID: 12357047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and clinical relevance of circulating CD4+CD28- T cells in Graves' disease.
    Wang F; Chen L; Shen Q; Liu T; Jiang L; Gu X; Chen L; Sun J; Liu C
    Immunol Lett; 2015 May; 165(1):47-51. PubMed ID: 25839128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of changes in the percentage of B (CD19) and T (CD3) lymphocytes, subsets CD4, CD8 and their memory (CD45RO), and naive (CD45RA) T cells in children with immune and non-immune thyroid diseases.
    Bossowski A; Urban M; Stasiak-Barmuta A
    J Pediatr Endocrinol Metab; 2003 Jan; 16(1):63-70. PubMed ID: 12585342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.
    Morgenthaler NG; Pampel I; Aust G; Seissler J; Scherbaum WA
    Horm Metab Res; 1998 Mar; 30(3):162-8. PubMed ID: 9566861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
    Morgenthaler NG; Ho SC; Minich WB
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
    Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of mouse monoclonal antibodies for identification of antigen regions of human thyroid peroxidase in adolescents with Graves' disease and non-toxic multinodular goiter by flow cytometry.
    Bossowski A; Stasiak-Barmuta A; Czarnocka B; Urban M; Dadan J
    Autoimmunity; 2005 Dec; 38(8):605-11. PubMed ID: 16390813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy.
    Kung AW; Jones BM
    J Clin Endocrinol Metab; 1998 Feb; 83(2):514-8. PubMed ID: 9467567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.